Sensun

Sensun Biopharma is a leading Chinese biotechnology company specializing in the research, development, and large-scale manufacturing of peptide drugs. Founded in 2001, the company operates across the entire peptide value chain, offering CDMO services for innovative drugs alongside a robust portfolio of generic peptide APIs and formulations. Its therapeutic focus spans metabolic diseases, cardiovascular health, and gastrointestinal disorders, with a particular emphasis on GLP-1 receptor agonists such as liraglutide and semaglutide. Sensun is listed on the Shanghai Stock Exchange (STAR Market) and is recognized for its advanced peptide synthesis platforms and GMP-compliant production facilities. The company serves both domestic and international markets, positioning itself as a key player in the global peptide pharmaceutical industry.